 NEW YORK and VIENNA, Austria, Aug. 05, 2021 GLOBE NEWSWIRE -- HOOKIPA Pharma Inc. NASDAQ: HOOK, HOOKIPA, a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that pre-clinical data on its replicating Lymphocytic choriomeningitis LCMV arenaviral-based immunotherapeutic has been published in the peer-reviewed journal, Nature Communications. The data demonstrate that HOOKIPAs LCMV-based vector, designed to target melanoma, modulated the tumor microenvironment and induced potent, tumor antigen-specific T cell responses, resulting in tumor regression and tumor cures in a pre-clinical setting. The publication is available online. 